^
    Back
    Association details:
    Biomarker:MET H1094Y
    Cancer:Non Small Cell Lung Cancer
    Drug:elzovantinib (TPX-0022) (Src kinase inhibitor, c-MET inhibitor, CSF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2022
    Title:

    Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).

    Published date:
    05/26/2022
    Excerpt:
    Confirmed partial responses to the MET tyrosine kinase inhibitor elzovantinib (TPX-0022) were observed in two patients with MET-TKD-mutant NSCLC and no other detectable driver mutations: a 64-year-old man with MET H1094Y-mutant NSCLC, and an 80-year-old man with MET F1200I-mutant NSCLC.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9124